For research use only. Not for therapeutic Use.
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1].
OSE-127 (4 days) blocks STAT5 phosphorylation in IL7-dependent ALL cell lines and patient derived xenograft (PDX) samples[2].
OSE-127 treated mice shows a reduction of peripheral blood (PB) blasts in 21/22 (95%) PDX samples in vivo when the corresponding control mice showed clinical signs of overt leukemia[1].
| Catalog Number | I042190 |
| CAS Number | 2375835-91-7 |
| Purity | ≥95% |
| Reference | [1]. Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS| NOVEMBER 15, 2022. [2]. Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren’s Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640. |
